Ning Zhang is an Assistant Professor in the Biology Department at James Madison University (JMU), joining in 2024. Her research focuses on enhancing crop resilience through molecular and biochemical studies of plant defense mechanisms against bacterial pathogens, alongside developing genome editing technologies for trait improvement. She holds a PhD in Horticulture and Crop Science from The Ohio State University (2016), an MS in Silviculture from Zhejiang Agriculture and Forestry University (2011), and a BS in Landscape Architecture from Shandong Agricultural University (2008). Research Interests: Dr. Zhang's lab investigates plant immunity pathways, CRISPR/Cas9 genome editing applications, and engineering crops for disease resistance. Her work integrates molecular biology, genetics, and biochemistry to tackle challenges posed by climate change and biotic/abiotic stresses. Recent Trends in Publications: Her articles concentrate on MAPK signaling pathways, NLR protein interactions, PP2C phosphatase regulation, and bacterial effector mechanisms in tomato and other crops. Key themes include immune system activation, pathogen recognition diversity, and transgenic plant development. Lab Information: The Zhang Lab at JMU is part of the Department of Biology, focusing on plant biotechnology solutions for agricultural sustainability. They collaborate on projects involving CRISPR-based gene editing and stress tolerance research.
Andre Levchenko is the John C. Malone Professor of Biomedical Engineering at Yale University, with secondary appointments in the Department of Neurosurgery and affiliations with the Cancer Signaling Networks, Immunology, and the Yale Program in Neurodevelopment and Regeneration. His research focuses on systems biology, signal transduction, and cell-cell communication, utilizing microfluidics and computational modeling to study cancer progression, stem cell behavior, and neurological disorders. PhD, Columbia University MEng, Moscow Institute of Physics and Technology Levchenko's work explores how cells process dynamic signals to make critical decisions, particularly in glioblastoma migration, organoid development, and cardiovascular tissue engineering. His lab develops innovative microfluidic platforms and mathematical models to dissect multicellular communication and signaling networks. Recent publications highlight his contributions to understanding YAP-driven cancer invasion , NOTCH signaling in angiogenesis , and metabolic regulation of hypoxia responses . He has pioneered methods for organoid modeling and single-cell analysis , advancing precision in biological signaling studies. Scientific Awards : Computational Molecular Biology Post-Doctoral Fellowship (Burroughs Wellcome Fund) National Academies Keck Futures Conference Invitee Distinguished Guest Lecturer, University of Virginia American Asthma Foundation Early Excellence Award Fellow, American Institute for Medical and Biological Engineering Levchenko leads the Levchenko Lab at the Yale Systems Biology Institute, collaborating with institutions like Mayo Clinic and Yale Cancer Center. His research has received recognition in Faculty of 1000 and multiple journal highlights.
Weiping Tang is a Professor of Pharmaceutical Sciences and Chemistry at the University of Wisconsin-Madison, holding the Janis Apinis Professorship in the School of Pharmacy and the Vilas Distinguished Achievement Professorship. He also serves as Director of the Medicinal Chemistry Center at the School of Pharmacy and maintains a faculty appointment with the Department of Chemistry in the College of Letters and Science. Janis Apinis Professor of Pharmaceutical Sciences Vilas Distinguished Achievement Professor Director of Medicinal Chemistry Center Faculty Appointment with Department of Chemistry Dr. Tang received his B.S. in Chemistry from Peking University in 1997, M.S. in Chemistry from New York University in 1999, Ph.D. in Organic Chemistry from Stanford University in 2005, and completed a postdoctoral fellowship in Medicinal Chemistry, Chemical Biology and Drug Discovery at Harvard University in 2007. Dr. Tang's research program focuses on drug discovery for cancer, infectious diseases, and neurodegenerative disorders through three interconnected areas: Organic Synthesis (advancing glycoscience through novel carbohydrate synthesis technologies), Medicinal Chemistry (developing small molecules that selectively remove disease-associated proteins), and Chemical Biology (dissecting biological pathways using novel small molecule probes). His group operates as an interdisciplinary team where chemists and biologists collaborate closely on drug discovery projects, with particular emphasis on developing novel degraders for disease-causing proteins. Analysis of Dr. Tang's publication record reveals a significant shift toward targeted protein degradation technologies, particularly PROTACs and molecular glues, while maintaining strong foundations in carbohydrate chemistry. His most impactful recent work includes developing degraders for extracellular and membrane proteins (previously considered 'undruggable'), creating rapid synthesis platforms like Rapid-TAC and Rapid-Glue, and advancing understanding of ternary complex formation for novel PROTAC design. His research spans both chemical methodology development and therapeutic applications across multiple disease areas. Vilas Distinguished Achievement Professorship Janis Apinis Professorship Numerous high-impact publications in leading chemistry and pharmacology journals Editor's pick and hot paper designations for significant contributions Dr. Tang mentors a diverse team of graduate students, postdoctoral fellows, and staff scientists with expertise spanning synthetic chemistry, medicinal chemistry, carbohydrate chemistry, computational chemistry, biochemistry, and cell biology. His group has developed innovative platforms for the rapid synthesis of protein degraders and has made significant contributions to understanding the mechanisms of action for these novel therapeutics. Current research includes developing selective degraders for cancer targets like RIPK1, BRD4, and CARM1, as well as advancing delivery systems for clinical translation. The Tang Research Group maintains state-of-the-art facilities within the School of Pharmacy at UW-Madison, equipped for comprehensive chemical synthesis, compound characterization, and biological evaluation. The group actively collaborates with researchers across campus and with industry partners to advance discoveries toward clinical applications, with particular focus on cancer therapeutics and protein degradation technologies.
Dr. Steven G. Clarke is a Distinguished Professor at UCLA Department of Chemistry & Biochemistry and director of research at the Molecular Biology Institute . His work bridges protein chemistry , methylation biology , and aging research through studies of spontaneous protein damage and its repair mechanisms. Education: BA in Chemistry and Zoology, Pomona College (magna cum laude, Phi Beta Kappa) PhD in Biochemistry and Molecular Biology, Harvard University (NSF Fellow) Postdoctoral Fellowship at UC Berkeley (Miller Fellow) Dr. Clarke's research focuses on protein isoaspartyl repair via PCMT1/PIMT enzymes , ribosomal protein methylation in Saccharomyces cerevisiae , and PRMT family characterization including PRMT7 and PRMT9. His lab combines biochemical assays , genetic models , and structural analysis to investigate aging mechanisms and disease implications. Recent publications highlight: COQ5 structure-function analysis in coenzyme Q biosynthesis PCMTD1 ubiquitin ligase interactions PRMT7 substrate specificity in histone H2B Protein isoaspartyl impacts on T cell function in lupus Novel PRMT inhibitors for cancer therapy Methionine addiction in osteosarcoma malignancy Major scientific awards: American Chemical Society Ralph F. Hirschmann Award in Peptide Chemistry NIH MERIT Award Ellison Medical Foundation Senior Scholar Award William C. Rose Award, ASBMB UCLA Distinguished Teaching Award (Eby Award winner) Current lab members include PhD candidates Eric Pang (UCSB) and Sining "Cindy" Wang (UCLA), while undergraduates Celeste Medina-Seymoure , Elizabeth Oroudjeva , Olivia Pacheco , and Jasmine Winter contribute to ongoing proteostasis studies. Collaborations with Profs. Jose Rodriguez and Catherine Clarke demonstrate interdisciplinary research approaches.
Rotem Karni, PhD, is an Associate Professor of Genetics at the Perelman School of Medicine, University of Pennsylvania, Philadelphia. He leads a research lab focused on understanding how alternative RNA splicing contributes to cancer and genetic diseases, with a strong emphasis on translating these findings into RNA-based therapies. Karni's lab develops decoy oligonucleotides, small molecules, and splice-switching technologies to modulate splicing factors and enhance immunotherapy. Education BSc in Biological Chemistry from The Hebrew University of Jerusalem (1997) PhD in Biological Chemistry from The Hebrew University of Jerusalem, Israel (2002) Postdoctoral Fellowship at Cold Spring Harbor Laboratory, NY (2002-2007) Karni's research explores the deregulation of alternative splicing in oncogenesis, particularly how splicing factors like RBFOX2 and S6K1 influence metastasis, DNA repair, and immune checkpoint modulation. His team investigates m6A RNA modifications for stabilizing mutant genes, with applications in Duchenne Muscular Dystrophy and pancreatic cancer. The lab's work is commercialized through biotech companies: SKIP Therapeutics, Andlit Therapeutics, and RNAble. Selected Research Trends RNA mis-splicing and neoantigen generation (2025) Splicing factor inhibition for tumor suppression (2023) Metastatic splicing signatures in pancreatic cancer (2023) Immune checkpoint splicing in cancer immunotherapy (2021) m6A modulation for mRNA stabilization (2023) Advising & Collaborations Karni has mentored numerous PhD and postdoctoral researchers, many of whom now hold leadership roles in academia, biotech, and medical institutions globally. His lab collaborates extensively on projects involving RNA innovation, including partnerships with the Institute for RNA Innovation. Contact Department of Genetics & Institute for RNA Innovation, One uCity Square, Room 4018, Philadelphia, PA 19104 Phone: 215-898-5072 Email: Rotem.Karni@Upenn.edu
Prof. Waldemar Kolanus leads the Molecular Immunology and Cell Biology department at the University of Bonn's Life & Medical Sciences Institute (LIMES) . His research bridges immunoregulation , stem cell dynamics , and metabolic stress responses in immune cells. Unit 2 member at LIMES Principal investigator in SFB 704 and ImmunoSensation Cluster Leads a multidisciplinary lab with postdocs, PhD students, and technical staff His work focuses on intracellular signaling pathways connecting immune activation to tissue homeostasis, particularly through: Cytohesin proteins in integrin-mediated adhesion and migration TRIM71 in stem cell regulation and congenital hydrocephalus High-salt environments affecting macrophage function Publication trends show expertise in immune cell migration , genetic models , and chemical inhibition , with frequent use of mice and zebrafish for in vivo studies. Key articles explore: TRIM71's dual role in auditory development and germ cell maintenance Cytohesin family's Golgi regulation and insulin signaling Ruxolitinib's off-target migration inhibition of dendritic cells Contact details: Address: LIMES Institute, Carl-Troll-Straße 31, Bonn Email: kolanus.sekretariat@uni-bonn.de Phone: +49 228 73-62788
Dr. Michael Wilczek is Assistant Teaching Professor in Biotechnology/Bioinformatics at Northeastern University's Roux Institute. His research bridges virology, bioinformatics, and educational innovation, with particular focus on JC polyomavirus pathogenesis and graduate education reform. Key research domains include: Molecular mechanisms of viral infections Bioinformatic analysis of host-pathogen interactions Observational health and real-world evidence Evidence-based graduate education His publication record demonstrates: Expertise in JC polyomavirus cellular pathways Innovative applications of machine learning in virology High-throughput drug screening methodologies Health disparities research in aging populations
Ying Ge is a Professor at the University of Wisconsin–Madison, jointly appointed in the Department of Cell and Regenerative Biology and the Department of Chemistry. Her research integrates chemistry, biology, and medicine, focusing on advanced mass spectrometry-based proteomic and metabolomic technologies to address cardiovascular diseases. Education: B.S., Peking University (1997) Ph.D., Cornell University (2002) Ying Ge's work centers on developing ultra high-resolution mass spectrometry platforms for top-down proteomics and metabolomics, applied to systems biology studies of heart failure and regenerative medicine. Key projects include myofilament protein modification mapping, stem cell therapy evaluation, and biomarker discovery for cardiac conditions. The 15 most recent articles highlight her lab's methodological innovations (e.g., photocleavable surfactants, native mass spectrometry) and biological discoveries in AMPK structural heterogeneity, RBM20-mediated cardiotoxicity, and sarcomere-metabolism cross-talk during regeneration. These publications span proteomics, metabolomics, structural biology, and clinical applications.
Prof. Ralph Hückelhoven is a Professor of Phytopathology at the Technical University of Munich (TUM), affiliated with the TUM School of Life Sciences. His research focuses on the molecular and biological mechanisms underlying plant diseases, particularly plant immunity, pathogen exploitation of signal transduction, and host-pathogen interactions. He leads the Chair of Phytopathology at TUM since 2006, following academic roles at universities of Kiel and Hohenheim. Education: PhD (1999) and habilitation in molecular phytopathology (2005) from Justus Liebig University Giessen, after a biology degree at RWTH Aachen University. Awards: Julius Kühn Prize (2004) and leadership of a DFG Junior Research Group (2002-2006). His research spans plant immunity at cellular and molecular levels, including studies on receptor kinases (e.g., MIK2, LORE), RAC GTPases (e.g., RACB), and metabolomics-driven insights into pathogen resistance. He has published over 100 peer-reviewed articles, examining topics like fungal toxins, volatile signaling, and crop disease management. Key publications include work on Arabidopsis immune receptors, barley powdery mildew susceptibility factors, and Fusarium head blight resistance. Research integrates genetics, proteomics, and metabolomics to advance disease-resistant crop development. His lab investigates host-pathogen interactions across scales—from molecular signaling to field epidemiology—contributing to sustainable agricultural strategies against plant pathogens.
Chiu Ping Cheng is a Professor in the Department of Biology at the University of Minnesota, USA, specializing in Molecular Biology and Plant-Microbe Interactions . With over two decades of research on Ralstonia solanacearum and its interactions with solanaceous crops, Dr. Cheng has pioneered studies on plant defense mechanisms against bacterial wilt, regulatory gene functions, and biocontrol agent applications. Current research: Plant-pathogen interactions Special techniques: Genomic screening, bacteriophage-derived proteins Key pathogens: Ralstonia solanacearum, Pectobacterium carotovorum His recent publications (2024) explore tomato cultivar resistance variation , NADPH oxidase-effector interactions , and phenylpropanoid metabolism in wild mungbean . Though no formal scientific awards are listed, his work has been featured in leading journals like Plant Cell & Environment and New Phytologist . Dr. Cheng operates from the Life Science Building R942 laboratory.
Prof. Dr. Urs F. Greber is an Ordinary Professor of Molecular Cell Biology at the Department of Molecular Life Sciences, Faculty of Mathematics and Natural Sciences, University of Zurich. His research focuses on understanding how viruses interact with host cells, particularly adenoviruses and rhinoviruses that cause human respiratory diseases. He leads the Greber Lab, which investigates viral entry mechanisms, replication processes, and the cellular responses to infection. Greber's research interests span virology, molecular cell biology, and infection mechanisms. His lab explores how viruses take control over membrane and lipid functions, cytoplasmic transport processes, and cellular metabolism to support their gene expression and progeny formation. They employ system-wide profiling, molecular cell biology approaches, light microscopy, and machine learning for image analysis to map the cell state underlying viral infections of cultured and primary human cells, including lung organoids and iPSC-derived macrophages. A key focus is understanding cell-to-cell variability in infection phenotypes and the mode-of-action of antiviral compounds. The Greber Lab has published extensively on adenovirus biology, including viral entry, uncoating, nuclear import, and assembly mechanisms. Their recent work has identified broad-spectrum antiviral compounds, elucidated alternative virus entry pathways, and developed innovative imaging and AI-based approaches for quantifying virus infectivity. Their research contributes to understanding how viruses break down host defense barriers and has implications for antiviral therapy development. Greber has supervised numerous PhD and Master's students including Cornelia Bircher, Alessandro Savi, Franziska Tomas, Alfonso Gomez-Gonzalez, Anthony Petkidis, and Dominik Olszewski. His lab has received funding from the Swiss National Science Foundation, including a grant for coronavirus research during the pandemic. The lab actively collaborates with other research groups at University of Zurich, ETH Zurich, and international institutions. Current projects include exploring how viral DNA interactions contribute to infection outcome variability, investigating adenovirus egress mechanisms, and developing high-throughput screening methods for antiviral compounds.
Feng Feng is an Assistant Professor in the Department of Biochemistry and Molecular Biology at Oklahoma State University, where he has been employed since August 2020. His research focuses on understanding how plants interact with microbial communities in their rhizosphere under various environmental conditions. Dr. Feng received his Ph.D. in Plant Molecular Biology from Tsinghua University in Beijing, China (2008-2012), followed by an M.S. in Microbiology and B.S. in Biotechnology from Henan Agricultural University in Zhengzhou, China. Ph.D., Plant Molecular Biology, Tsinghua University, Beijing, China (2008-2012) M.S., Microbiology, Henan Agricultural University, Zhengzhou, China (2005-2008) B.S., Biotechnology, Henan Agricultural University, Zhengzhou, China (2001-2005) Dr. Feng's research interests center on plant-microbe interactions, particularly how plants balance immunity and symbiosis signaling pathways when encountering both pathogenic and beneficial microbes in the rhizosphere. His work examines how environmental conditions affect plant decisions to promote or inhibit microbial colonization, with the goal of developing cropping systems that require less chemical fertilizer and are more resilient to climate change. Using molecular, cell biology, genetic, and biochemical approaches, his lab investigates how abiotic environmental factors regulate plant-microbe interactions and how immunity and symbiosis signaling pathways influence broader microbial communities. Dr. Feng's scholarly output shows a consistent focus on plant immunity and symbiosis mechanisms, particularly involving LysM receptor-like kinases and their role in distinguishing between pathogenic and symbiotic microbial signals. His recent work has increasingly emphasized the ecological context of plant-microbe interactions and the potential applications for sustainable agriculture. Dr. Feng serves as an Associate Editor for Frontiers in Microbiology (since 2022) and has editorial roles with several other journals including Frontiers in Plant Science, Horticultural Plant Journal, and iMeta. Associate Editor, Frontiers in Microbiology (2022-present) Editorial Board, Frontiers in Plant Science (2021-present) Editorial Board, Horticultural Plant Journal (2021-present) Editorial Board, iMeta (2021-present) Dr. Feng actively mentors graduate students and postdoctoral researchers, with his lab currently recruiting Ph.D. students and postdocs interested in plant-microbe interactions. He has secured multiple research grants including funding from the U.S. Department of Agriculture and the Oklahoma Center for the Advancement of Science and Technology (OCAST). His laboratory investigates the molecular mechanisms by which plants regulate their interactions with rhizosphere communities, with particular focus on how environmental conditions influence the balance between immunity and symbiosis signaling pathways.
Prof. Oliver Seitz leads the Bioorganic Synthesis research group at the Department of Chemistry, Faculty of Mathematics and Natural Sciences, Humboldt University of Berlin. His lab focuses on cutting-edge chemical biology approaches for protein/nucleic acid interrogation, with recent work advancing DNA/RNA-programmed assemblies for cellular imaging and therapeutic applications. Research spans chemical protein synthesis, glycoprotein/phosphoprotein engineering, and nucleic acid-templated reactions. Key innovations include Forced Intercalation (FIT) probes for wash-free RNA imaging, loss-of-affinity principles for catalytic efficiency, and peptide-PNA conjugates for targeted cellular delivery. The group actively develops tools for live-cell protein labeling and biomolecular spatial screening. Recent publications (2021-2024) emphasize fluorescence-based detection systems, catalytic templated reactions, and therapeutic peptide synthesis. Trends show increasing sophistication in multi-dye probes, glycan engineering, and RNA-triggered pro-drug activation. Scientific awards include: Max Bergmann Award (2019) Prof. Seitz actively advises doctoral students, with recent graduates Marvin Björn Stutz (2023, magna cum laude ), Dino Gluhacevic von Krüchten (2023, summa cum laude ), and Sophie Schöllkopf (2023, magna cum laude ). Current PhD candidates include Ekaterina Kazakova (glycoprotein synthesis), Alina Herfort (phosphoproteins), and Lina-Marie Beck (peptide-nucleic acid conjugates), with postdocs like Dr. Mandana Oloub (viscosity sensors). The Bioorganic Synthesis lab operates within Berlin's vibrant chemical research ecosystem, utilizing specialized techniques for chemical protein synthesis and nucleic acid detection. Recent team growth reflects ongoing projects in RNA imaging, catalytic templated reactions, and therapeutic conjugate development, supported by open positions for new researchers.
Tyler Johnson, PhD, is an Associate Professor in the Department of Natural Sciences and Mathematics at Dominican University of California's School of Health and Natural Sciences. His expertise lies in Natural Products Chemistry , Bioorganic Chemistry , and Medicinal Chemistry , with a focus on biomedical applications. Johnson's research emphasizes discovering therapeutic lead compounds and molecular probes from marine and terrestrial natural products. His research team investigates chemotypes like mycothiazole , zampanolide , fijianolide , and latrunculin from Indo-Pacific marine sponges. These compounds exhibit potent cytotoxicity (IC50 1~5 nM) against cancer cell lines through mechanisms including microfilament disruption , mitochondrial complex I inhibition , and microtubule stabilization . Current work explores mycothiazole as a molecular probe for mitochondrial aging. Key publications span 2024-2002, covering topics from sponge-derived anticancer agents to inflammation modulation and environmental toxicology. Johnson's laboratory engages in large-scale natural product isolation, spectroscopic validation, and semi-synthetic medicinal chemistry to optimize therapeutic leads. His work integrates undergraduate and graduate students into interdisciplinary biomedical research.
Scott Garman is Professor of Biochemistry at UMass Amherst, focusing on structural biology of glycoproteins in human diseases. PhD from Harvard University. Research areas: Lysosomal enzyme mechanisms in storage diseases (Fabry, Schindler); Malaria surface protein structures; Antibody-receptor interactions. Utilizes X-ray crystallography to study enzyme mutations causing disease. Key findings: Determined structures of α-galactosidase (Fabry disease) and α-NAGAL (Schindler disease), revealing molecular bases for enzyme dysfunction. Developed models for enzyme trafficking and substrate processing. Laboratory: Investigates protein folding diseases and develops therapeutic strategies. Collaborates on malaria vaccine development and antibody engineering.
